Moreover, tumor cells did not seem to have enough enzymes to act on pro-IGF-2; thus, the excess pro-IGF-2 competes with IGF-1 and IGF-2 in binding to IGFBP to form a 40–50–kDa binary complex. The gene discussed is IGF2; the disease is neoplasm.